Leuprorelin Sandoz

Leuprorelin, the active ingredient in Leuprorelin Sandoz, is a gonadotropin‑releasing hormone (GnRH) agonist presented as a sterile solution for subcutaneous use. It is employed in hormonal therapy for prostate cancer, endometriosis, uterine fibroids and precocious puberty.

GNH USA supplies Leuprorelin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuprorelin acts on the GnRH pathway and is used in several hormone‑dependent conditions.

- Prostate cancer: reduces testosterone production to slow tumor growth. - Endometriosis: suppresses estrogen levels to alleviate pelvic pain and lesion progression. - Uterine fibroids: decreases hormone stimulation to shrink fibroid size and improve symptoms. - Precocious puberty: halts early activation of the hypothalamic‑pituitary‑gonadal axis.

Leuprorelin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Injection site pain or erythema - Decreased libido - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Cardiovascular events (e.g., myocardial infarction) - Severe allergic reactions (anaphylaxis) - Bone mineral density loss leading to fractures - Hormonal withdrawal syndrome - Liver function abnormalities

When prescribing Leuprorelin, clinicians should consider several safety measures.

- Cardiovascular risk assessment: evaluate history of heart disease before initiation. - Bone health monitoring: perform baseline densitometry and follow‑up scans. - Hormonal effects: monitor testosterone or estrogen levels during therapy. - Diabetes management: watch for glucose intolerance or worsening diabetes. - Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin): may reduce Leuprorelin effectiveness. - Anticoagulants (e.g., warfarin): increased risk of bleeding due to hormonal changes. - Hormone replacement therapy: antagonizes intended hormone suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: possible alteration of glucose control. - Corticosteroids: may exacerbate bone loss. - Opioids: may mask pain related to disease progression.